Inflammatory Bowel Disease

VANCOUVER, British Columbia — Patients with ulcerative colitis were more likely to achieve clinical response and steroid-free clinical remission at 8 to 16 weeks on upadacitinib vs. ustekinumab, according to a presenter.

VANCOUVER, British Columbia — In this Healio video exclusive, Neslyne B. Augustin, MD, reviews the case of a patient with ulcerative colitis and concomitant SARS-CoV-2 infection, which she presented at the ACG Annual Scientific Meeting.

VANCOUVER, British Columbia — Patients with inflammatory bowel disease treated with biologics had lower risk for cardiovascular and thromboembolic events, and those on oral small molecules were not at increased risk, a presenter noted here.

VANCOUVER, British Columbia — In a Healio video exclusive, Edward V. Loftus Jr., MD, FACG, discusses results from the INSPIRE trial, in which more patients with ulcerative colitis achieved clinical remission on IV risankizumab vs. placebo.

VANCOUVER, British Columbia — The outgoing ACG president delivered his address at the 2023 Annual Scientific Meeting, highlighting the college’s many achievements and ongoing collegiality, as well as his personal gratitude to colleagues.

VANCOUVER, British Columbia — In a Healio video exclusive, Jan Wehkamp, MD, PhD, discusses results from the QUASAR study, in which Tremfya outperformed placebo in clinical response at weeks 12 and 24 among patients with ulcerative colitis.

An app-based digital therapeutic was “largely effective” in reducing symptoms and improving quality of life, work productivity and health literacy among patients with irritable bowel syndrome, according to late-breaking data from UEG Week.

Skyrizi demonstrated non-inferiority to Stelara in clinical remission at 24 weeks, as well as superiority in endoscopic remission at 48 weeks, in patients with moderate to severe Crohn’s disease, according to data presented at UEG Week.